Literature DB >> 361145

Hyperbaric oxygen: the Medical Research Council trials and their clinical significance.

S Dische.   

Abstract

The clinical trials of the use of hyperbaric oxygen in radiotherapy conducted by the Medical Research Council's working party have shown that local cure and survival can be improved in head and neck and cervical cancer. Evidence for benefit has been presented in carcinoma of bronchus, but none has so far been found in carcinoma of the bladder. Although hyperbaric oxygen has produced increased effect upon normal tissues as well as upon tumour, a real improvement in therapeutic ratio appears to be present. The future use of hyperbaric oxygen in radiotherapy will depend upon a comparison of effectiveness with other methods now being tested to improve radiotherapy. The trials have yielded much fundamental and clinical data of general relevance in the radiotherapy of malignant disease.

Entities:  

Mesh:

Year:  1978        PMID: 361145     DOI: 10.1259/0007-1285-51-611-888

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  15 in total

1.  [Clinical trials--what is the question?].

Authors:  R Guttenberger
Journal:  Med Klin (Munich)       Date:  1999-04-15

Review 2.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

Review 3.  Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

Authors:  M Saunders; S Dische
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 4.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 5.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

6.  Interstitial diffuse optical probe with spectral fitting to measure dynamic tumor hypoxia.

Authors:  Leonard Che Fru; Steven L Jacques; Kwang P Nickel; Tomy Varghese; Michael W Kissick; Larry A DeWerd; Randall J Kimple
Journal:  Biomed Phys Eng Express       Date:  2020-01-31

Review 7.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 8.  Molecular aspects of tumour hypoxia.

Authors:  Saskia E Rademakers; Paul N Span; Johannes H A M Kaanders; Fred C G J Sweep; Albert J van der Kogel; Johan Bussink
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

Review 9.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 10.  Experimental results and clinical implications of the four R's in fractionated radiotherapy.

Authors:  K R Trott
Journal:  Radiat Environ Biophys       Date:  1982       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.